Jazz Pharmaceuticals PLC
J7Z
Company Profile
Business description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact
Waterloo Road
Fifth Floor, Waterloo Exchange
DublinD04 E5W7
IRLT: +353 16347800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,800
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
We view the shares are materially overvalued.
stocks
Chart of the Week: Lithium is rebounding on rising demand
The mining sector is significantly overvalued on average but select value to be found.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,317.60 | 22.80 | -0.24% |
| CAC 40 | 8,429.03 | 0.00 | 0.00% |
| DAX 40 | 25,278.21 | 279.81 | 1.12% |
| Dow JONES (US) | 49,662.66 | 129.47 | 0.26% |
| FTSE 100 | 10,686.18 | 130.01 | 1.23% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,753.63 | 175.25 | 0.78% |
| Nikkei 225 | 57,598.83 | 454.99 | 0.80% |
| NZX 50 Index | 13,406.57 | 159.55 | 1.20% |
| S&P 500 | 6,881.31 | 38.09 | 0.56% |
| S&P/ASX 200 | 9,088.40 | 22.10 | -0.24% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |